RESUMO
BACKGROUND: Cutaneous microdialysis (CM) is an ex vivo technique that allows study of tissue chemistry, including bioavailability of actual tissue concentration of unbound drug in the interstitial fluid of the body. AIM: To test the penetration and dermal bioavailability of galenic formulations of the small-molecule IP10.C8, a dual-protease inhibitor of the dipeptidyl peptidase and aminopeptidase families. METHODS: Using CM, we tested the penetration and dermal bioavailability of IP10.C8 into the dermis and subcutis of pigs, and determined the tissue concentration of IP10.C8 enzymatically, using an enzyme activity assay (substrate Gly-Pro-pNA) and high performance liquid chromatography. RESULTS: Dermal bioavailability was enhanced by using microemulsion or the addition of the penetration enhancer oleic acid to a hydroxyethylcellulose (HEC) gel formulation. Dermal bioavailability was also enhanced when galenic formulations were prepared with higher pH (7.5 vs. 6.5) or higher drug concentration (5% vs. 1%) in HEC gel. CONCLUSION: It seems possible, using CM for topical skin penetration testing in anaesthetized domestic pigs, to test the bioavailability of newly designed drugs. However, the experimental time is limited due to the anaesthesia, and is dependent on drug recovery. Validation of this technique for routine use is challenging, and more experiments are needed to validate this preclinical set-up.
Assuntos
Dipeptidil Peptidases e Tripeptidil Peptidases/antagonistas & inibidores , Microdiálise , Absorção Cutânea , Administração Cutânea , Animais , Disponibilidade Biológica , Composição de Medicamentos , Ensaios Enzimáticos , Modelos Animais , Projetos Piloto , SuínosRESUMO
AIM: The point of time for total knee arthroplasty has a significant importance due to limited implant survival rate. To what extent the preoperative stage of physical and psychological function limitation, which is increasing with the progression of the osteoarthritis, has an influence on the early functional outcome after total knee arthroplasty should be clarified in a clinical evaluation. PATIENTS AND METHOD: 47 Patients were treated with the same bicondylar knee endoprosthesis system (Type Genia, ESKA Implants, Lübeck). A clinical evaluation was undertaken preoperatively and at 3 and 6 months postoperatively using HSS score, WOMAC index and SF-36 score. In relation to the preoperative HSS score the patients were allocated into three groups depending upon whether their level of function was "good", "average" or "poor". Additionally, all patients were assigned to three body mass index (BMI) groups (< 30, 30 - 35, > 35) which were descriptively analysed. RESULTS: The preoperative differences in HSS score and SF-36 score in all three groups show a high reduction after 3 and 6 months. Postoperatively there were no significant differences in all three groups at both timepoints. Patients with "poor" preoperative function achieved on average a lower score niveau than patients with preoperative "good" function, but have the benefit of the best function improvement. The early postoperative period (3 months) showed the highest decrease in physical and psychological function derogation. The BMI had no significant influence on the early functional outcome. CONCLUSION: Therefore, older people should receive early total knee arthroplasty to gain a high postoperative score niveau. In younger patients the indication for implant should be considered essentially because of the limited survival rate. Even in progressive osteoarthritis and extreme functional limitation the bicondylar surface replacement gives the possibility of a good early functional postoperative outcome. Total knee arthroplasty of obese patients is under attention of the perioperative internistic risks, a safe procedure with good functional results and can increase patient's mobility.
Assuntos
Artroplastia do Joelho/métodos , Osteoartrite do Joelho/cirurgia , Complicações Pós-Operatórias/fisiopatologia , Amplitude de Movimento Articular/fisiologia , Idoso , Idoso de 80 Anos ou mais , Índice de Massa Corporal , Feminino , Seguimentos , Humanos , Prótese do Joelho , Masculino , Pessoa de Meia-Idade , Satisfação do Paciente , Qualidade de Vida , Fatores de RiscoRESUMO
The annual number of total knee replacement implantations is rising continuously. A progressive cutaneous hypersensitivity rate against metallic materials in the population has been registered which can lead to an increase of allergy-induced reactions associated with implant loosening in the future although the correlation with an allergic cutaneous sensitisation has not been proven in all cases. On apparent allergy against metallic implant components different alternative solutions to standard endoprostheses should be taken into account for primary implantation or revision of total knee replacement, for example the application of implant components without metallic elements (e.g. ceramics), the use of non-allergic metallic implants, such as titanium or ZrNb alloys, or potential allergy-inducing metallic materials after masking the implant surface using a suitable coating. In the case of primary or revision surgery most patients with metal allergy are treated with a Ti(Nb)N-coated knee implant made of cobalt-chrome or titanium alloys in our hospital. Within an international multi-centre study we are currently implanting a newly developed knee endoprosthesis system with a ceramic femoral component as an alternative.
Assuntos
Hipersensibilidade/etiologia , Hipersensibilidade/prevenção & controle , Prótese do Joelho/efeitos adversos , Metais/efeitos adversos , Complicações Pós-Operatórias/etiologia , Complicações Pós-Operatórias/prevenção & controle , Adulto , Ligas , Cerâmica , Materiais Revestidos Biocompatíveis , Dermatite Alérgica de Contato/etiologia , Dermatite Alérgica de Contato/prevenção & controle , Dermatite Alérgica de Contato/cirurgia , Humanos , Hipersensibilidade/cirurgia , Molibdênio , Complicações Pós-Operatórias/cirurgia , Desenho de Prótese , Falha de Prótese , Reoperação , Titânio , ZircônioRESUMO
BACKGROUND AND OBJECTIVE: Anaesthesia may affect the regulatory balance of postoperative immune response. The aim of this study was to investigate the effects of different volatile and non-volatile anaesthetic agents and particularly of clinically used agent combinations on the proliferation capacity and cytokine production of immune cells. METHODS: Peripheral blood mononuclear cells from healthy donors were PHA-activated in the presence or absence of various concentrations of thiopental, propofol, fentanyl, sufentanil, sevoflurane, nitrous oxide and combinations of these anaesthetics. Cell proliferation was assessed by tritiated thymidine uptake. Interleukin-2 production and release of the soluble IL-2 receptor were determined by enzyme immunoassays and used as measures of lymphocyte activation. RESULTS: Thiopental inhibited cell proliferation in a dose dependent manner (P < 0.001) and reduced sIL-2R release (2090-970 microg mL(-1); P < 0.05). Propofol reduced sIL-2R release at the high concentration of 10 microg mL(-1) (2220 pg mL(-1) 1780 microg mL(-1); p < 0.05). Fentanyl and sufentanil did not compensate for or enhance the inhibitory effects of thiopental. Nitrous oxide, but not sevoflurane, reduced the proliferation of human peripheral blood mononuclear cells (P < 0.05). In combinations with thiopental or nitrous oxide, sevoflurane compensated the inhibitory effects of these two agents. Fentanyl, sufentanil, sevoflurane and nitrous oxide did not affect PHA-induced IL-2 and sIL-2 receptor release by human peripheral blood mononuclear cells. CONCLUSION: Thiopental and nitrous oxide have immunosuppressive activity. In contrast, sevoflurane may have a beneficial effect by alleviating the immunosuppressive effects of both substances.
Assuntos
Anestésicos/farmacologia , Imunidade Celular/efeitos dos fármacos , Adulto , Anestésicos Inalatórios/farmacologia , Anestésicos Intravenosos/farmacologia , Divisão Celular/efeitos dos fármacos , Relação Dose-Resposta a Droga , Combinação de Medicamentos , Humanos , Técnicas In Vitro , Interleucina-2/sangue , Pessoa de Meia-Idade , Monócitos/efeitos dos fármacos , Monócitos/imunologia , Fito-Hemaglutininas/farmacologia , Receptores de Interleucina-2/biossíntese , Linfócitos T/efeitos dos fármacos , Linfócitos T/imunologiaRESUMO
Helicobacter pylori is the key pathogen for gastroduodenal diseases. The clinical outcome of H. pylori infection is influenced by the presence of strain-specific virulence factors that are usually detected by the presence of specific anti-H. pylori antibodies in serum. Apart from the detection of these antibodies by enzyme-linked immunosorbent assay (ELISA), it is desirable to obtain additional information concerning the presence of certain virulence factors of H. pylori that are currently detected by immunoblot analysis. At present, the immunodiagnosis of an H. pylori infection includes two separate methods: ELISA and immunoblot analysis. Here, we report the development and evaluation of a new rapid flow microparticle immunofluorescence assay (FMIA) for detection of anti-H. pylori antibodies in human serum. The assay allows rapid qualitative and quantitative detection of anti-H. pylori antibodies by using crude antigen preparations as well as single recombinant antigens (urease A, urease B, CagA, and alkylhydroxy peroxide reductase) in the same sample with one measurement, and thus it combines the advantages of enzyme immunoassay and Western blot analysis. Seventy-five patient samples were analyzed by FMIA, ELISA, and Western blotting with respect to their immunoreactivity against crude H. pylori extracts and individual H. pylori antigens. Statistical analyses revealed an overall similarity of more than 90% among the results for FMIA, ELISA, and Western blot. Therefore, we conclude that FMIA is a powerful and time- and cost-saving assay system for the detection of antimicrobial antibodies, with higher sensitivity and a larger measurement range than ELISA.
Assuntos
Anticorpos Antibacterianos/sangue , Imunofluorescência/métodos , Helicobacter pylori/imunologia , Antígenos de Bactérias/genética , Sequência de Bases , Western Blotting/métodos , DNA Bacteriano/genética , Ensaio de Imunoadsorção Enzimática/métodos , Gastroenterite/diagnóstico , Gastroenterite/imunologia , Infecções por Helicobacter/diagnóstico , Infecções por Helicobacter/imunologia , Helicobacter pylori/genética , Humanos , Proteínas Recombinantes/genética , Proteínas Recombinantes/imunologiaRESUMO
Complex perioperative immunodysfunction occurs in patients with renal cell carcinoma undergoing nephrectomy. Here, the effect of pretreatment with IL-2 is addressed. Of 63 patients who underwent tumour nephrectomy, 26 patients received four doses of 10 Mio IE/m2 IL-2 b.d. s.c. (i.e. a total of 40 Mio IE/m2) a week before operation, 37 did not. Parameters of cellular and humoral immunity (differential blood count, T-cell markers CD2, CD3, CD4, and CD8, B-cell markers CD19 and CD20, monocyte markers CD13 and CD14, NK-cell marker CD16, activation markers CD25, CD26, CD69 and HLA-DR, and cytokines IL-1-receptor antagonist (IL-1RA), IL-2, soluble IL-2-receptor (sIL-2R), IL-6, IL-10, and TGFbeta) were measured in peripheral venous blood. Blood was drawn before IL-2, one day before and immediately after the operation, and on the 1st, 3rd, 5th, and 10th postoperative day. All patients showed postoperatively elevated leukocyte and granulocyte counts, and elevated serum levels of cytokines IL-6 and IL-10. T-cell and activation markers were decreased. However, all these alterations were less accentuated in patients who had been pretreated with IL-2. Monocyte counts and IL-2 and TGFbeta levels were decreased, but IL-1RA and sIL-2R levels were elevated in pretreated patients. IL-2-related toxicity was WHO grade I-II in all patients, grade III in one patient. The anaesthetic regimen had no measurable effect. IL-6 concentrations were higher in renal venous than in venous pool blood, indicating IL-6 production in the tumour in vivo. Tumour-specific survival was better in pretreated patients with tumours extending beyond the kidney. Pretreatment with IL-2 modulates perioperative immunodysfunction in patients undergoing tumour nephrectomy. This affects in particular T-cell-mediated immunity and levels of cytokines IL-10 and IL-6. The IL-2 application scheme used here was followed by distinct counter regulation including monocytes, IL-2, sIL-2R, IL-1RA and TGFbeta. Taken together, pretreatment with IL-2 may complement surgery in the treatment of patients with renal cell carcinoma, and may help close the therapeutic gap between neo-adjuvant and adjuvant immunotherapy.
Assuntos
Carcinoma de Células Renais/imunologia , Síndromes de Imunodeficiência/tratamento farmacológico , Interleucina-2/farmacologia , Neoplasias Renais/imunologia , Metástase Neoplásica/tratamento farmacológico , Cuidados Pré-Operatórios/métodos , Adulto , Idoso , Antígenos de Superfície/sangue , Linfócitos B/efeitos dos fármacos , Linfócitos B/imunologia , Biomarcadores/sangue , Carcinoma de Células Renais/complicações , Carcinoma de Células Renais/cirurgia , Citocinas/sangue , Humanos , Síndromes de Imunodeficiência/imunologia , Síndromes de Imunodeficiência/prevenção & controle , Interleucina-2/uso terapêutico , Neoplasias Renais/complicações , Neoplasias Renais/cirurgia , Contagem de Leucócitos , Pessoa de Meia-Idade , Metástase Neoplásica/imunologia , Metástase Neoplásica/fisiopatologia , Nefrectomia/efeitos adversos , Receptores de Citocinas/sangue , Taxa de Sobrevida , Linfócitos T/efeitos dos fármacos , Linfócitos T/imunologia , Resultado do TratamentoRESUMO
OBJECTIVE: Complex peri-operative immuno-dysfunction occurs in patients with renal cell carcinoma undergoing nephrectomy. Here, the effect of pretreatment with interleukin-2 (IL-2) is addressed. METHODS: Of 63 patients who underwent tumor nephrectomy, 26 patients received 4 doses of 10 Mio IE/m(2) IL-2 b.d. s.c. (i.e. a total of 40 Mio IE/m(2)) a week before operation, 37 did not. Parameters of cellular and humoral immunity (differential blood count, T-cell markers CD2, CD3, CD4, and CD8, B-cell markers CD19 and CD20, monocyte markers CD13 and CD14, NK (natural killer)-cell marker CD16, activation markers CD25, CD26, CD69, and HLA-DR, and cytokines IL-1-receptor antagonist (IL-1RA), IL-2, soluble IL-2-receptor (sIL-2R), IL-6, IL-10, and TGFbeta) were measured in venous blood. Blood was drawn before IL-2, 1 day before and immediately after the operation, and on the 1st, 3rd, 5th, and 10th postoperative day. RESULTS: All patients showed postoperatively elevated leukocyte and granulocyte counts, and elevated serum levels of cytokines IL-6 and IL-10. T-cell and activation markers were decreased. However, all these alterations were less accentuated in patients who had been pretreated with IL-2. Monocyte counts and IL-2 and TGFbeta levels were decreased, but IL-1RA and sIL-2R levels were elevated in pretreated patients. IL-2 related toxicity was WHO grades I-II in all patients, grade III in one patient. The anesthetic regimen had no measurable effect. IL-6 concentrations were higher in renal venous than in venous pool blood, indicating IL-6 production in the tumor in vivo. CONCLUSIONS: Pretreatment with IL-2 modulates peri-operative immuno-dysfunction in patients undergoing tumor nephrectomy. This affects in particular T-cell-mediated immunity and levels of cytokines IL-10 and IL-6. The IL-2 administration scheme used here was followed by distinct counter-regulation including monocytes, IL-2, sIL-2R, IL-1RA and TGFbeta.
Assuntos
Carcinoma de Células Renais/tratamento farmacológico , Carcinoma de Células Renais/imunologia , Interleucina-2/uso terapêutico , Neoplasias Renais/tratamento farmacológico , Neoplasias Renais/imunologia , Adulto , Idoso , Linfócitos B , Biomarcadores Tumorais/sangue , Carcinoma de Células Renais/sangue , Carcinoma de Células Renais/cirurgia , Feminino , Humanos , Neoplasias Renais/sangue , Neoplasias Renais/cirurgia , Masculino , Pessoa de Meia-Idade , Nefrectomia , Pré-Medicação , Linfócitos TRESUMO
OBJECTIVE: Cardiopulmonary bypass (CPB) triggers systemic inflammation. Recent evidence suggests that metabolic and oxygenation management can affect the outcome of patients after cardiac surgery. We investigated the influence of oxidant/antioxidant and protease/antiprotease imbalance during the course of systemic and pulmonary inflammation. METHODS: In a study of 61 patients, we measured the intracellular thiol concentration, the intracellular activity of cathepsins and elastase, and the concentrations of secreted elastase, soluble alpha(1)-proteinase inhibitor (alpha(1)-PI), and secretory leukoprotease inhibitor (SLPI). Peripheral blood and BAL fluid (BALF) were obtained preoperatively and 2 h after CPB. RESULTS: A post-CPB depletion of thiol was found in blood granulocytes, lymphocytes, and monocytes, as well as BALF lymphocytes and macrophages. The degree of postoperative depletion correlated with PO(2) and blood glucose levels during CPB. Concomitant reduction of FEV(1) showed positive correlation with thiol depletion of blood monocytes and granulocytes. Elastase and cathepsin activities were increased in blood cells but not in lymphocytes or macrophages from BALF. The concentrations of secreted elastase were significantly increased in blood plasma but not in BALF. Enhanced antiprotease (alpha(1)-PI, SLPI) concentrations were measured in BALF but not in peripheral blood. CONCLUSIONS: The inflammatory response of the intra-alveolar compartment is clearly distinguishable from systemic inflammation. CPB causes a differentiated impairment of the antioxidant defense system as well as a protease/antiprotease imbalance in blood and BALF. Oxygenation under circumstances of CPB and concomitant pulmonary disease, as well as blood glucose metabolism, influence the antioxidative defense. Individual perioperative management of blood glucose and oxygenation could improve cellular defense systems in the peripheral blood and BALF and therefore result in a more favorable patient outcome.
Assuntos
Antioxidantes/metabolismo , Líquido da Lavagem Broncoalveolar/química , Ponte Cardiopulmonar , Inibidores de Proteases/metabolismo , Contagem de Células Sanguíneas , Glicemia/análise , Procedimentos Cirúrgicos Cardíacos , Ponte Cardiopulmonar/efeitos adversos , Catepsinas/sangue , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Oxigênio/sangue , Elastase Pancreática/metabolismo , Proteínas Secretadas Inibidoras de Proteinases , Proteínas/metabolismo , Inibidor Secretado de Peptidases Leucocitárias , Compostos de Sulfidrila/sangue , Síndrome de Resposta Inflamatória Sistêmica/etiologia , Síndrome de Resposta Inflamatória Sistêmica/metabolismo , alfa 1-Antitripsina/metabolismoRESUMO
Cathepsin K is a cysteine protease with high matrix-degrading activity. Initially, cathepsin K was described as being expressed exclusively by osteoclasts. It was suggested that cathepsin K expression is a specific feature of cells involved in bone remodelling. The aim of this study was to investigate the hypothesis that cathepsin K is expressed not only in bone-resorbing macrophages, but also more generally in specifically differentiated macrophages, such as epithelioid cells and multinucleated giant cells in soft tissues. Specimens obtained from different organs and anatomical locations of patients suffering from sarcoidosis, tuberculosis, granulomas caused by foreign materials, and sarcoid-like lesions were investigated for the expression of cathepsins B, K, and L. Immunohistochemistry and in situ hybridization showed cathepsin K in epithelioid cells and multinucleated giant cells irrespective of the pathological condition and anatomical location, but not in normal resident macrophages. By immunoelectron microscopy, cathepsin K was discovered in cytoplasmic granules of multinucleated giant cells. In contrast, cathepsin B and cathepsin L were expressed ubiquitously in CD68-positive tissue macrophages, epithelioid cells, and multinucleated giant cells. The results demonstrate that cathepsin K, but not cathepsin B or cathepsin L, differentiates specific phenotypes of macrophages independently of the anatomical site. Its enzymatic characteristics, particularly its high matrix-degrading activity, suggest that cathepsin K-positive epithelioid cells and multinucleated giant cells are characterized by an enhanced specific proteolytic capability.
Assuntos
Catepsinas/análise , Macrófagos/enzimologia , Sarcoidose/enzimologia , Adulto , Idoso , Biomarcadores/análise , Catepsina B/análise , Catepsina K , Catepsina L , Diferenciação Celular , Cisteína Endopeptidases , Células Epitelioides/enzimologia , Feminino , Células Gigantes/enzimologia , Granuloma de Corpo Estranho/enzimologia , Humanos , Imuno-Histoquímica/métodos , Hibridização In Situ , Linfonodos/enzimologia , Macrófagos Alveolares/enzimologia , Masculino , Microscopia Imunoeletrônica , Pessoa de Meia-Idade , Tuberculose/enzimologiaRESUMO
The thickness shear mode (TSM)-sensor responds to changes of mechanical properties of the material contacting the surface of the sensor. One of the material properties is the viscosity of a liquid. Abiosensor based on the TSM-resonator for the detection of endotoxin has been developed. It exploits the viscosity-density change during the reaction of endotoxin with limulus amebocyte lysate (LAL). The effect of surface properties of the sensor has been investigated to achieve better output signals. It is shown that the sensor requires a hydrophilic surface to get a better coupling between the sensor and the LAL-endotoxin solution. The TSM biosensor is able to detect an endotoxin concentration as low as 100 fg/ml by using only 50-microl standard LAL solution. The disadvantages of reusable sensors, such as the contamination from previous measurement of endotoxin and the cost of the regeneration or reclining processes of the sensor, have been eliminated by using a cost effective disposable TSM-sensor.
Assuntos
Técnicas Biossensoriais/instrumentação , Endotoxinas/análise , Animais , Fenômenos Biomecânicos , Técnicas Biossensoriais/métodos , Técnicas Biossensoriais/normas , Endotoxinas/normas , Teste do Limulus/instrumentação , Teste do Limulus/métodos , Teste do Limulus/normas , Modelos Teóricos , Quartzo , ViscosidadeRESUMO
PURPOSE: Patients with renal cell carcinoma have an impaired function of the immune system, which is the basis for different approaches of immunotherapy. We address perioperative changes of several parameters of the immune system in these patients. MATERIALS AND METHODS: Parameters of cellular and humoral immunity, including differential blood count, T cell markers CD2, 3, 4 and 8, B cell markers CD19 and 20, monocyte markers CD13 and 14, natural killer cell marker CD16, activation markers CD25, CD26 and HLA-DR, and cytokines interleukin-1 (IL-1) receptor antagonist, IL-2, soluble IL-2 receptor, IL-6, IL-10 and transforming growth factor-beta, were measured in the venous blood of patients who underwent renal surgery extracorporeal shock wave lithotripsy (ESWL, Dornier Medical Systems, Inc., Marietta, Georgia). Patients were grouped and age matched, and 37 underwent tumor nephrectomy, 20 open renal surgery for nonmalignant reasons and 24 ESWL. A group consisting of 39 controls received no treatment. RESULTS: Little change was detected in controls and those patients who received ESWL. Patients who underwent open renal surgery had increased leukocyte and granulocyte counts until postoperative day 3 but had low T cell counts. The postoperative decrease in CD25 expressing cells corresponded to an increase in the soluble IL-2-receptor. Cytokines IL-6 and 10, which also have immunosuppressive properties, were markedly increased postoperatively. These changes were more noted (p <0.01) in those patients who underwent tumor nephrectomy than open renal surgery for nonmalignant reasons and remained detectable when paired patients with similar surgical trauma were compared. In tumor nephrectomy cases renal venous IL-6 was higher than peripheral venous levels. CONCLUSIONS: Patients with renal cell carcinoma suffer from selective immuno-dysfunction, indicating a rationale for perioperative immunomodulation.
Assuntos
Carcinoma de Células Renais/imunologia , Neoplasias Renais/imunologia , Adulto , Idoso , Idoso de 80 Anos ou mais , Antígenos CD/sangue , Carcinoma de Células Renais/cirurgia , Humanos , Interleucinas/sangue , Neoplasias Renais/cirurgia , Pessoa de Meia-Idade , Cuidados Pós-OperatóriosRESUMO
Recent studies have demonstrated that atrial fibrillation (AF) occurs in the presence of degenerative changes of atrial tissue. In contrast, bradykinin (BK) appears to have cardioprotective effects diminishing myocardial hypertrophy and fibrosis. It is unknown, however, whether AF has direct effects on BK metabolism. Therefore, the purpose of this study was to determine the atrial expression of the membrane-bound peptidases, also referred to as ectopeptidases, carboxypeptidase M (CPM), dipeptidyl peptidase IV (DPIV), and alanyl-aminopeptidase (APN) in patients with and without AF. Atrial tissue samples of 35 patients undergoing open heart surgery were examined. Seventeen patients had chronic persistent AF (> or = 6 months; CAF), the remaining 18 patients (controls) had no history of AF. Peptidase expression was analyzed at the mRNA (quantitative RT-PCR) level and apparent changes were confirmed at the protein level. In case of unaltered mRNA levels, enzyme activity was determined. Reduced amounts of CPM-mRNA were found in patients with CAF (41.3+/-9.7 U nu controls: 86.1+/-17.5 U P<0.05). CPM protein was decreased to 47.5% in patients with CAF compared with controls (P<0.01). DPIV and APN mRNA amounts were similar in both groups. DPIV activity, however, was increased during CAF (219.6+/-30 pkat/mg protein v controls: 195.8+/-21.8 pkat/mg P<0.05). APN activity was unchanged. In conclusion, atrial bradykinin metabolizing activities are significantly altered during AF in humans. The observed alterations in ectopeptidase expression/activity may play a role in the structural remodeling of fibrillating atria.
Assuntos
Fibrilação Atrial/enzimologia , Antígenos CD13/metabolismo , Dipeptidil Peptidase 4/metabolismo , Átrios do Coração/enzimologia , Metaloendopeptidases/metabolismo , Bradicinina/metabolismo , Antígenos CD13/genética , Dipeptidil Peptidase 4/genética , Proteínas Ligadas por GPI , Expressão Gênica , Humanos , Metaloendopeptidases/genéticaRESUMO
During continuous ambulatory peritoneal dialysis (CAPD) the peritoneal immune cells, mainly macrophages, are highly compromised by multiple factors including oxidative stress, resulting in a loss of functional activity. One reason for the increase of inflammatory reactions could be an imbalance in the thiol-disulfide status. Here, the possible protective effects of the antioxidant flavonoid complex silymarin and its major component silibinin on the cellular thiol status were investigated. Peritoneal macrophages from dialysis fluid of 30 CAPD patients were treated with silymarin or silibinin up to 35 days. A time-dependent increase of intracellular thiols was observed with a nearly linear increment up to 2.5-fold after 96 hours, reaching a maximum of 3.5-fold after 20 days of culture. Surface-located thiols were also elevated. The stabilization of the cellular thiol status was followed by an improvement of phagocytosis and the degree of maturation as well as significant changes in the synthesis of IL-6 and IL-1ra. Furthermore, the treatment of peritoneal macrophages with flavonoids in combination with cysteine donors resulted in a shortened and more efficient time course of thiol normalization as well as in a further increased phagocytosis. In addition, GSH-depletion in thiol-deficient media simulating CAPD procedures led to intracellular thiol deficiency similar to the in vivo situation. It is concluded that treatment with milk thistle extracts silymarin and silibinin alone or, more effectively in combination with cysteine donors, provide a benefit for peritoneal macrophages of CAPD-patients due to a normalization and activation of the cellular thiol status followed by a restoration of specific functional capabilities.
Assuntos
Macrófagos Peritoneais/efeitos dos fármacos , Diálise Peritoneal Ambulatorial Contínua , Silimarina/farmacologia , Compostos de Sulfidrila/metabolismo , Acetilcisteína/farmacologia , Adulto , Idoso , Antígenos CD/biossíntese , Células Cultivadas/efeitos dos fármacos , Corantes , Cisteína/fisiologia , Feminino , Citometria de Fluxo , Fluoresceínas/análise , Regulação da Expressão Gênica/efeitos dos fármacos , Glutationa/fisiologia , Humanos , Proteína Antagonista do Receptor de Interleucina 1 , Interleucina-6/biossíntese , Interleucina-6/genética , Masculino , Pessoa de Meia-Idade , Estresse Oxidativo , Diálise Peritoneal Ambulatorial Contínua/efeitos adversos , Fagocitose/efeitos dos fármacos , Sialoglicoproteínas/biossíntese , Sialoglicoproteínas/genéticaRESUMO
The aims of this study were to investigate the role of cathepsin K in the pathology of amyloidosis by demonstrating its presence in multinucleated giant cells (MGCs) adjacent to amyloid deposits, and determining its ability to degrade amyloid fibril proteins in vitro. The study was performed using autopsy and biopsy specimens from patients with AA or AL amyloidosis. In six (55%) patients with AA amyloidosis and seven (58%) patients with AL amyloidosis, variable numbers of CD68-immunoreactive MGCs were found adjacent to amyloid deposits. In each case strong cytoplasmic immunostaining for cathepsin K was found in MGCs; immunostaining of amyloid deposits was present in five (45%) patients with AA amyloidosis and three (25%) patients with AL amyloidosis. In vitro degradation experiments showed that recombinant cathepsin K completely degraded AA amyloid fibril proteins at pH 5.5 as shown by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and Western blotting. Less effective degradation took place at pH 7.4 and there was no degradation in the presence of a general cysteine protease inhibitor (E64) or in the absence of cathepsin K. This is the first study to show that cathepsin K is expressed in MGCs adjacent to amyloid deposits and to demonstrate its ability to degrade amyloid fibril proteins.
Assuntos
Amiloide/metabolismo , Amiloidose/enzimologia , Catepsinas/fisiologia , Adulto , Idoso , Amiloide/ultraestrutura , Precursor de Proteína beta-Amiloide/metabolismo , Amiloidose/metabolismo , Amiloidose/patologia , Catepsina K , Catepsinas/imunologia , Catepsinas/metabolismo , Feminino , Células Gigantes/metabolismo , Humanos , Imuno-Histoquímica , Técnicas In Vitro , Masculino , Microscopia Eletrônica , Pessoa de Meia-Idade , Baço/metabolismo , Baço/patologiaRESUMO
In addition to the mechanisms inducing the expression and secretion of cytokines under distinct pathophysiological conditions, the fate of cytokines after secretion at sites of inflammation is a field of growing interest. Proteolysis has been suggested to be a fundamental mechanism of regulating the activities of various components of the cytokine network. Evidence grows that besides highly specific cytokine converting proteases such as interleukin-1beta-converting enzyme or tumor necrosis factor-converting enzyme, neutrophil-derived serine proteases are intimately involved in the modulation of the activities of cytokines and their receptors. Particularly at sites of inflammation, high amounts of the active serine proteases elastase, cathepsin G, and proteinase 3 are released from infiltrating polymorphonuclear cells in close temporal correlation to elevated levels of inflammatory cytokines, strongly indicating that these proteases are involved in the control of cytokine bioactivity and availability.
Assuntos
Citocinas/metabolismo , Neutrófilos/enzimologia , Neutrófilos/patologia , Serina Endopeptidases/fisiologia , Humanos , Hidrólise , Inflamação/enzimologia , Inflamação/imunologia , Inflamação/patologia , Neutrófilos/imunologia , Neutrófilos/metabolismo , Serina Endopeptidases/metabolismoRESUMO
CD26 or dipeptidyl peptidase IV (DP IV) is expressed on various cell types, including T cells. Although T cells can receive activating signals via CD26, the physiological role of CD26/DP IV is largely unknown. We used the reversible DP IV inhibitor Lys[Z(NO(2))]-pyrrolidide (I40) to dissect the role of DP IV in experimental autoimmune encephalomyelitis (EAE) and to explore the therapeutic potential of DP IV inhibition for autoimmunity. I40 administration in vivo decreased and delayed clinical and neuropathological signs of adoptive transfer EAE. I40 blocked DP IV activity in vivo and increased the secretion of the immunosuppressive cytokine TGF-beta1 in spinal cord tissue and plasma during acute EAE. In vitro, while suppressing autoreactive T cell proliferation and TNF-alpha production, I40 consistently up-regulated TGF-beta1 secretion. A neutralizing anti-TGF-beta1 Ab blocked the inhibitory effect of I40 on T cell proliferation to myelin Ag. DP IV inhibition in vivo was not generally immunosuppressive, neither eliminating encephalitogenic T cells nor inhibiting T cell priming. These data suggest that DP IV inhibition represents a novel and specific therapeutic approach protecting from autoimmune disease by a mechanism that includes an active TGF-beta1-mediated antiinflammatory effect at the site of pathology.
Assuntos
Dipeptidil Peptidase 4/metabolismo , Encefalomielite Autoimune Experimental/enzimologia , Encefalomielite Autoimune Experimental/prevenção & controle , Fator de Crescimento Transformador beta/metabolismo , Regulação para Cima , Animais , Divisão Celular/imunologia , Células Cultivadas , Encefalomielite Autoimune Experimental/imunologia , Encefalomielite Autoimune Experimental/patologia , Ativação Enzimática/efeitos dos fármacos , Ativação Enzimática/imunologia , Feminino , Adjuvante de Freund/administração & dosagem , Inibidores do Crescimento/fisiologia , Terapia de Imunossupressão , Injeções Intraperitoneais , Injeções Subcutâneas , Ativação Linfocitária , Lisina/administração & dosagem , Lisina/análogos & derivados , Lisina/farmacologia , Camundongos , Proteína Básica da Mielina/administração & dosagem , Proteína Básica da Mielina/imunologia , Inibidores de Proteases/administração & dosagem , Inibidores de Proteases/farmacologia , Pirrolidinas/administração & dosagem , Pirrolidinas/farmacologia , Subpopulações de Linfócitos T/imunologia , Fator de Crescimento Transformador beta/biossíntese , Fator de Crescimento Transformador beta/fisiologia , Fator de Crescimento Transformador beta1 , Regulação para Cima/efeitos dos fármacos , Regulação para Cima/imunologiaRESUMO
Cathepsins B and L are commonly expressed cysteine proteinases that play a major role in lysosomal bulk proteolysis, protein processing, matrix degradation, and tissue remodeling. Cathepsins are also implicated in tumor progression and metastasis, tissue injury, and inflammation. Cells at sites of inflammation often show upregulation and secretion of cathepsins. The regulation of cathepsin expression by inflammatory mediators is not well understood. The aims of this study were to investigate the effect of the cytokines interleukin-1 beta (IL-1 beta), IL-6, IL-10, transforming growth factor-beta 1 (TGF-beta 1), and hepatocyte growth factor (HGF) on expression of cathepsin B and cathepsin L mRNA (quantitative RT-PCR), on protein expression (ELISA, Western blot), and also on enzymatic activity of cathepsins B and L. Investigations were performed using the human lung epithelial cell line A-549. IL-6 was found to induce a concentration-dependent increase in mRNA expression, protein concentration, and enzymatic activity of cathepsin L. Cathepsin B mRNA and protein expression were not affected by IL-6. In contrast, TGF-beta 1 decreased the amount of cathepsin L mRNA and cathepsin B mRNA. At protein level, it was shown that TGF-beta 1 clearly reduced the concentration of cathepsin L but not cathepsin B. The cytokines IL-1 beta, IL-10, and HGF were found to exert no effect on cathepsin B and L expression. In conclusion, these results are the first to show that IL-6 and TGF-beta 1 have opposite effects on the regulation of expression of cathepsins B and L in A-549 human lung epithelial cells. The proinflammatory cytokine IL-6 induced an upregulation of cathepsin L, whereas TGF-beta 1 suppressed cathepsin B and L expression. Further studies are needed to clarify the mechanism that affects cathepsin B and L expression.
Assuntos
Catepsina B/biossíntese , Catepsinas/biossíntese , Endopeptidases , Células Epiteliais/enzimologia , Interleucina-6/fisiologia , Pulmão/enzimologia , Fator de Crescimento Transformador beta/fisiologia , Catepsina B/antagonistas & inibidores , Catepsina B/genética , Catepsina L , Catepsinas/antagonistas & inibidores , Catepsinas/genética , Linhagem Celular , Cisteína Endopeptidases , DNA/antagonistas & inibidores , DNA/biossíntese , Relação Dose-Resposta Imunológica , Ativação Enzimática/imunologia , Células Epiteliais/imunologia , Humanos , Pulmão/citologia , Pulmão/imunologia , RNA Mensageiro/antagonistas & inibidores , RNA Mensageiro/biossíntese , Fator de Crescimento Transformador beta1RESUMO
In increasing numbers of pulmonary diseases an association with a loss of intracellular thiols, mainly glutathione, is postulated. Therefore, the quantitative measurement of thiols within different viable cells is a possible metabolic parameter for cellular function and defense capacity of all pulmonary immune cells including alveolar macrophages (AM), that are highly compromised by oxidative stress. In this study the cellular thiol content was determined using fluorochrom conjugated chloromethyl derivatives (5-chloromethylfluorescein diacetate, CMFDA) in flow cytometry. The procedure was evaluated in vitro using biochemical techniques for glutathione quantification. Based on this approach, AM obtained from bronchoalveolar lavage (BAL) of smokers and patients with chronic obstructive pulmonary disease (COPD) showed a significant thiol deficiency compared to a nonsmoker/non-COPD group. The cellular thiol expression of AM from smokers and COPD patients reached only 50 and 53% of the control group. Lowest thiol concentrations (47% of control) were detected within the smoker(+)/COPD(+) group. This intracellular thiol deficiency significantly correlated with reduced lung function (FEV(1), PaO(2)). With regard to the tightly regulated thiol metabolism of immune cells, these results imply the onset of functional disturbances in thiol deficient AM. The determination of the cellular thiol content of AM, obtained from BAL by flow cytometry, presents a simple and reliable tool to monitor the effect of therapeutic measures focusing on the stabilization of the cellular thiol status.
Assuntos
Pneumopatias Obstrutivas/metabolismo , Macrófagos Alveolares/metabolismo , Fumar , Compostos de Sulfidrila/análise , Idoso , Líquido da Lavagem Broncoalveolar/citologia , Citometria de Fluxo , Fluoresceínas , Corantes Fluorescentes , Glutationa/análise , Humanos , Macrófagos Alveolares/química , Pessoa de Meia-Idade , Estresse OxidativoRESUMO
BACKGROUND: Induction of programmed cell death is assumed to be a possible effect of extracorporeal photoimmunotherapy (ECPI). OBJECTIVE: In the present study lymphocytes of patients with cutaneous T cell lymphoma undergoing ECPI were investigated for early apoptotic events. METHODS: Annexin V, known for its selective affinity to phospholipids, was used to detect early phases of apoptosis. Simultaneous staining with propidium iodide binding to DNA allowed detection of late apoptotic/necrotic cells. RESULTS: At 1 h after ECPI, an increase in early apoptotic cells was found indicating a direct effect of ECPI. At 20 h after each ECPI session, a delayed increase in the number of apoptotic lymphocytes was observed in early apoptotic annexin-stained cells and in late apoptotic cells, whereas in nonirradiated cells no remarkable changes were found. Apoptosis was confirmed by altered light scattering properties and DNA fragmentation. CONCLUSION: The apoptotic cell death of reinfused lymphocytes is supposed to be a therapeutic effect of ECPI.
Assuntos
Anexina A5/metabolismo , Apoptose , Linfócitos/metabolismo , Linfoma Cutâneo de Células T/patologia , Idoso , Fragmentação do DNA , DNA de Neoplasias/genética , Eletroforese em Gel de Ágar , Feminino , Citometria de Fluxo , Humanos , Imunoterapia , Linfócitos/citologia , Linfoma Cutâneo de Células T/metabolismo , Linfoma Cutâneo de Células T/terapia , Masculino , Pessoa de Meia-Idade , Fototerapia , Ligação Proteica , Fatores de TempoRESUMO
Using synthetic inhibitors, it has been shown that the ectopeptidase dipeptidyl peptidase IV (DP IV) (CD26) plays an important role in the activation and proliferation of T lymphocytes. The human immunodeficiency virus-1 Tat protein, as well as the N-terminal nonapeptide Tat(1-9) and other peptides containing the N-terminal sequence XXP, also inhibit DP IV and therefore T cell activation. Studying the effect of amino acid exchanges in the N-terminal three positions of the Tat(1-9) sequence, we found that tryptophan in position 2 strongly improves DP IV inhibition. NMR spectroscopy and molecular modeling show that the effect of Trp(2)-Tat(1-9) could not be explained by significant alterations in the backbone structure and suggest that tryptophan enters favorable interactions with DP IV. Data base searches revealed the thromboxane A2 receptor (TXA2-R) as a membrane protein extracellularly exposing N-terminal MWP. TXA2-R is expressed within the immune system on antigen-presenting cells, namely monocytes. The N-terminal nonapeptide of TXA2-R, TXA2-R(1-9), inhibits DP IV and DNA synthesis and IL-2 production of tetanus toxoid-stimulated peripheral blood mononuclear cells. Moreover, TXA2-R(1-9) induces the production of the immunosuppressive cytokine transforming growth factor-beta1. These data suggest that the N-terminal part of TXA2-R is an endogenous inhibitory ligand of DP IV and may modulate T cell activation via DP IV/CD26 inhibition.